Pt-141 Side Effects
PT-141 Side Effects: What the Trials Report
The short answer
Nausea was the most common adverse event in the phase 3 RECONNECT trials, reported by about 40 percent of participants who received bremelanotide (PT-141) (Kingsberg et al., 2019).
This page is general educational information, research-use framing only, not medical advice. Any decision about a research compound belongs with a qualified clinician.
What are the most common PT-141 side effects?
The most common PT-141 side effect is nausea, reported by about 40 percent of participants who received bremelanotide in the phase 3 RECONNECT trials, with flushing and headache close behind (Kingsberg et al., 2019).
RECONNECT was two randomized, placebo-controlled phase 3 trials of bremelanotide (PT-141) in premenopausal women with hypoactive sexual desire disorder, where participants self-injected the drug under the skin as needed (Kingsberg et al., 2019). The trials reported that most side effects were mild or moderate and tied to the timing of a dose (Kingsberg et al., 2019).
| Adverse event | How often it was reported | Source |
|---|---|---|
| Nausea | Most common, about 40% of bremelanotide users | Kingsberg et al., 2019 |
| Flushing | Among the next most common | Kingsberg et al., 2019 |
| Headache | Among the next most common | Kingsberg et al., 2019 |
| Injection site reactions | Reported | Kingsberg et al., 2019 |
| Vomiting | Reported, less common than nausea | Kingsberg et al., 2019 |
| Transient blood pressure rise, heart rate drop | Reported after dosing | Kingsberg et al., 2019 |
| Focal skin darkening (hyperpigmentation) | Reported with repeated dosing | Kingsberg et al., 2019 |
Why does PT-141 cause nausea?
PT-141 (bremelanotide) works by activating melanocortin receptors, and that same signaling is closely tied to nausea, which is why it led the side-effect list in trials (Kingsberg et al., 2019).
In the RECONNECT trials, nausea was the single most reported event at about 40 percent, and some participants stopped treatment because of it (Kingsberg et al., 2019). The trials described the events overall as mostly mild or moderate, but frequency is a group-level finding, not a prediction for any one person.
Does PT-141 raise blood pressure?
Yes, the RECONNECT trials recorded transient increases in blood pressure and small decreases in heart rate in the hours after a dose (Kingsberg et al., 2019).
Because of this pattern, the approved product label carries a caution against use in people with uncontrolled high blood pressure or known cardiovascular disease. The trial reports described the changes as transient, but whether that pattern is safe for a given person is a clinician's judgment, not something a research summary can answer (Kingsberg et al., 2019).
Can PT-141 change your skin color?
Yes, repeated dosing was associated with focal hyperpigmentation, a darkening of the skin, gums, or face, in some participants during the trials (Kingsberg et al., 2019).
The reason ties back to the mechanism: melanocortin receptors also act on pigment-producing cells in skin, so the pathway involved in desire signaling can also drive pigment changes (Kingsberg et al., 2019). Unlike nausea or flushing, this effect can be longer lasting than the events tied to a single dose.
How long do PT-141 side effects last?
In the trials, the common events like nausea, flushing, and headache were generally short-lived and linked to the timing of a dose, while pigment changes could last longer (Kingsberg et al., 2019).
The blood pressure and heart rate shifts were also reported as transient after each dose (Kingsberg et al., 2019). None of this is a guarantee about how long any effect would last for a specific reader, which is why timing and follow-up belong with a clinician.
What dose of PT-141 did the trials study?
In the RECONNECT trials, participants received a single 1.75 mg subcutaneous injection of bremelanotide, taken as needed before anticipated activity (Kingsberg et al., 2019).
This is what the research reported, not a recommendation. The product label also limits how often a dose may be used. Any personal dose, schedule, or decision to use PT-141 at all belongs with a qualified clinician who knows your history.
Who does the label say should avoid PT-141?
The product label advises against PT-141 for people with uncontrolled high blood pressure or known cardiovascular disease, based on the transient blood pressure rise seen in trials (Kingsberg et al., 2019).
Bremelanotide was studied and approved in a specific group, premenopausal women with hypoactive sexual desire disorder, so its safety in other groups is not established by these trials (Kingsberg et al., 2019). A clinician can weigh your full history against these findings.
Has PT-141 been studied outside RECONNECT?
Bremelanotide was also studied in earlier development work, but the strongest published safety data come from the phase 3 RECONNECT trials, so those are the findings this page relies on (Kingsberg et al., 2019).
The pattern RECONNECT documented, nausea and flushing leading the list, fits the melanocortin mechanism, which is why nausea, flushing, and headache are the events most often described for this compound rather than a longer or more severe list.
Pt-141 Side Effects: FAQ
Sourcing research-grade peptides?
Talk to the Peptara Labs team about purity, third-party certificates of analysis, and cold-chain shipping.
References
- Kingsberg SA, Clayton AH, Portman D, Williams LA, Krop J, Jordan R, Lucas J, Simon JA. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstet Gynecol. 2019;134(5):899 to 908. doi:10.1097/AOG.0000000000003500 (PMID 31599840). The RECONNECT phase 3 trials that documented nausea near 40 percent, flushing, headache, transient blood pressure rise, and focal hyperpigmentation with bremelanotide.
General educational information only, research-use framing, not medical advice. Confirm the current status where you live and consult a qualified professional before acting.